Sign In
Buy DXCM
$86.94
-0.370 (-0.424%)
At Close: Aug 04, 2026
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics
06:30pm, Thursday, 01'st May 2025
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
DexCom (DXCM) Q1 Earnings Miss Estimates
06:20pm, Thursday, 01'st May 2025
DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.
Dexcom beats quarterly sales estimates, reiterates annual forecast
04:54pm, Thursday, 01'st May 2025
Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
04:02pm, Thursday, 01'st May 2025
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
11:55am, Wednesday, 30'th Apr 2025
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key Metrics
10:21am, Tuesday, 29'th Apr 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for DexCom (DXCM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
10:05am, Tuesday, 29'th Apr 2025
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
07:34pm, Tuesday, 22'nd Apr 2025
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc.
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
04:30pm, Tuesday, 22'nd Apr 2025
NEW YORK , April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fi
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
06:30pm, Friday, 18'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs
12:51pm, Wednesday, 16'th Apr 2025
What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
08:50am, Wednesday, 16'th Apr 2025
SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc.
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
02:05pm, Friday, 11'th Apr 2025
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
01:28pm, Thursday, 10'th Apr 2025
The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.
